FINWIRES · TerminalLIVE
FINWIRES

Indian Equities Slip on Thursday Amid Profit Booking in Heavyweights

-- Indian benchmark indices closed marginally lower on Thursday as profit booking in select large stocks offset early optimism.

The BSE Sensex slipped 122.56 points, or 0.2%, to finish at 77,988.68, while the NSE Nifty 50 fell 34.55 points, or 0.1%, to close at 24,196.75.

Sentiment remained mildly supported by expectations of a second round of US-Iran talks aimed at easing the ongoing conflict. Uncertainty over timing, however, kept investors cautious.

On the macro side, India's Wholesale Price Index (WPI) inflation rose to 3.88% in March, up from 2.13% in February, according to government data released late on Wednesday. Goods and services exports also declined 4.58% year-on-year to $74.11 billion in March.

Among stocks, HDFC Asset Management Company (NSE:HDFCAMC, BOM:541729) reported a slight dip in consolidated profit to 6.23 billion rupees in Q4 FY26 from 6.38 billion rupees a year earlier. Revenue from operations rose to 10.5 billion rupees from 9.01 billion rupees, according to its filing.

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) gained after receiving US FDA approval for Methotrexate Injection in both multi-dose and single-dose vials. The drug is used in cancer treatment as well as autoimmune conditions including rheumatoid arthritis and psoriasis.

Related Articles

Asia

Shakti Pumps (India) Invests INR100 Million in EV Mobility Unit

Shakti Pumps (India) (NSE:SHAKTIPUMP, BOM:531431) said it has invested 100 million Indian rupees in its wholly owned subsidiary Shakti EV Mobility by subscribing to 10 million equity shares, according to a Tuesday filing to the Indian stock exchanges.Shares of the company rose 1% in Wednesday's trade.With this, Shakti Pumps' total investment in the EV mobility unit has increased to 650 million Indian rupees, the filing said.The investment is aimed at supporting business expansion of the subsidiary, it added.

$BOM:531431$NSE:SHAKTIPUMP
Asia

Challenger's Fiscal 2026 Q3 Update Missed Consensus Across Key Life Metrics, Jarden Says

Challenger's (ASX:CGF) fiscal 2026 third-quarter update missed consensus across key Life metrics, with FM outflows significantly worse than expected, driven by institutional equity mandate attrition in both Australian and global equities, according to a Tuesday note by Jarden.The firm's redemption of all CGFPC notes on May 25 simplifies the capital structure, reduces the AT1 coupon burden, and is earnings-per-share accretive.Jarden sees balanced risk/reward for Challenger in the future, with catalysts including capital management flexibility from the Australian Prudential Regulation Authority reform, as well as expanding retirement partnerships across superfunds.It lowered its fiscal 2026 sales forecast to reflect weaker institutional fixed-term sales, partially offset by higher retail annuity sales as partnerships come online.The investment firm retained its neutral rating on Challenger and raised the price target to AU$8.70 per share from AU$8.60 per share.

$ASX:CGF
Asia

Proya Cosmetics 2025 Profit Down 4%, Revenue Slips 2%

Proya Cosmetics (SHA:603605) posted 2025 attributable net profit of 1.50 billion yuan, down 3.5% from 1.55 billion yuan the previous year.Earnings per share slid to 3.80 yuan from 3.92 yuan, according to a Wednesday filing with the Shanghai bourse.Operating revenue declined 1.7% year over year to 10.6 billion yuan from 10.8 billion yuan.Shares of the cosmetics maker were up over 1% in recent trade.

$SHA:603605